Primary Aldosteronism: Clinical Characteristics of Patients with a Paradoxical Increase in P-Aldosterone in Response to Captopril Challenge Test

Abstract

A proportion of patients with primary aldosteronism (PA) have a paradox increasein plasma-Aldosterone (P-Aldosterone) concentration (PAC) during the Captopril Challenge Test (CCT). This study aimed to investigate if a paradoxical rise in PAC during CCT, was associated with clinical characteristics or outcomes inpatients with PA. We hypothesized that a paradoxical response to CCT is ameasure of disease severity, reflected by a higher baseline aldosterone/renin-ratio (ARR). A retrospective study of patients with PA,confirmed by CCT, who were referred for adrenal venous sampling between May 2011and August 2021 were eligible. Patients with an increase in PAC>10% frombaseline during CCT were classified as cases, while patients with 10 to 30% suppression were classified as controls. Of 167 patients referred, 116 (70%) were eligible for this study. Based on the CCT, 61/116 (53%) were classified as cases while 55/116 (47%) were classified as controls. The baseline ARR was 122 pmol/mIU (IQR: 65 to 223) for cases and 137 pmol/mIU (IQR: 65 to 223) for controls (p=0.66). Cases had lower systolic blood pressure (p=0.02) and higherpotassium levels (p=0.05) compared to controls. Complete clinical remission was obtained in 22 of 31 (71%) of the cases and 13 of 27 (48%) of the controls (p=0.03) after adrenalectomy. In conclusion, a paradoxical response to CCT wasnot associated with ARR. By contrast, patients with a paradoxical response did have lower systolic blood pressure, higher potassium levels, and markedly higher odds of full clinical remission after adrenalectomy.

Keywords

primary aldosteronism - captopril challenge test - paradoxical response - clinical remission

Publikationsverlauf

Eingereicht: 23. Oktober 2024

Angenommen nach Revision: 23. Januar 2025

Artikel online veröffentlicht:
06. März 2025

• References

• 1 Käyser SC, Dekkers T, Groenewoud HJ. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826-2835
• 2 Libianto R, Russell GM, Stowasser M. et al. Detecting primary aldosteronism in Australian primary care: a prospective study. Med J Aust 2022; 216: 408-412
• 3 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 4 Leung AA, Symonds CJ, Hundemer GL. et al. Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis. Hypertension 2022; 79: 1835-1844
• 5 Zhu R, Shagjaa T, Rossitto G. et al. Exclusion tests in unilateral primary aldosteronism (ExcluPA) study. J Clin Endocrinol Metab 2023; 108: 496-506
• 6 Nanba K, Tamanaha T, Nakao K. et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab 2012; 97: 1688-1694
• 7 Jahan S, Yang J, Hu J. et al. Captopril challenge test: an underutilized test in the diagnosis of primary aldosteronism. Endocr Connect 2024; 13: e230445
• 8 Wada N, Miyoshi A, Usubuchi H. et al. Prediction of unilateral hyperaldosteronism on adrenal vein sampling using captopril challenge test in patients with primary aldosteronism. Endocr J 2021; 68: 45-51
• 9 Voss N, Mørup S, Clausen C. et al. Prognostic value of contralateral suppression on kidney function after surgery in patients with primary aldosteronism. Clin Endocrinol (Oxf) 2023; 98: 306-314
• 10 Mørup S, Voss N, Clausen C. et al. Prognostic value of contralateral suppression for remission after surgery in patients with primary aldosteronism. Clin Endocrinol (Oxf) 2022; 96: 793-802
• 11 O’Shea PM, Griffin TP, Browne GA. et al. Screening for primary aldosteronism using the newly developed IDS-iSYS^® automated assay system. Pract Lab Med 2016; 7: 6-14
• 12 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
• 13 Rossi GP, Maiolino G, Seccia TM. Adrenal venous sampling: where do we atand?. Endocrinol Metab Clin North Am 2019; 48: 843-858
• 14 Liu X, Guo C, Bian J. et al. Captopril challenge test in the diagnosis of primary aldosteronism: consistency between 1- and 2- h sampling. Front Endocrinol (Lausanne) 2023; 14: 1183161
• 15 Gideon A, Sauter C, Fieres J. et al. Kinetics and interrelations of the renin aldosterone response to acute psychosocial stress: a neglected stress system. J Clin Endocrinol Metab 2020; 105: e762-e773
• 16 Stathori G, Alexakis D, Chrousos GP. et al. Examining aldosterone plasma concentration alterations post-ACTH stimulation in healthy subjects: a systematic literature review and meta-analysis on ACTH’s role in aldosterone secretion. Hormones (Athens) 2024; 23: 765-775